InMed Pharmaceuticals (INM) Accumulated Expenses (2020 - 2026)
InMed Pharmaceuticals' (INM) quarterly Accumulated Expenses came in at $373540.0 in Q1 2026, down 19.61% year-on-year from $464665.0 in Q1 2025, and down 0.83% quarter-over-quarter from $376656.0 in Q4 2025.
InMed Pharmaceuticals (INM) Accumulated Expenses (2020 - 2026) Analysis & Trends
InMed Pharmaceuticals' Accumulated Expenses history runs 7 years deep, the most recent figure standing at $373540.0 for Q1 2026.
- On a quarterly basis, Accumulated Expenses fell 19.61% year-over-year to $373540.0 in Q1 2026; TTM through Mar 2026 was $373540.0, a 19.61% decrease from a year earlier, with the FY2025 full-year figure at $417927.0, down 14.41% from the prior year.
- Accumulated Expenses fell to $373540.0 in Q1 2026 per INM's latest filing, from $376656.0 in the prior quarter.
- Across five years, Accumulated Expenses topped out at $488278.0 in Q2 2024 and bottomed at $54629.0 in Q1 2024.
- The 5-year median for Accumulated Expenses is $308396.0 (2023), against an average of $276138.4.
- Across the five-year window, Accumulated Expenses sank 69.41% in 2024 and jumped 750.58% in 2025, its largest moves.
- Year by year, Accumulated Expenses stood at $139120.0 in 2022, then fell by 26.84% to $101775.0 in 2023, then jumped by 231.35% to $337236.0 in 2024, then advanced by 11.69% to $376656.0 in 2025, then retreated by 0.83% to $373540.0 in 2026.
- Per Business Quant, the three latest INM Accumulated Expenses figures stand at $373540.0 (Q1 2026), $376656.0 (Q4 2025), and $274250.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | InMed Pharmaceuticals | 307,858.50 | -4.93 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 373,540.00 |
| Dec 31, 2025 | 376,656.00 |
| Sep 30, 2025 | 274,250.00 |
| Jun 30, 2025 | 417,927.00 |
| Mar 31, 2025 | 464,665.00 |
| Dec 31, 2024 | 337,236.00 |
| Sep 30, 2024 | 85,521.00 |
| Jun 30, 2024 | 488,278.00 |
| Mar 31, 2024 | 54,629.00 |
| Dec 31, 2023 | 101,775.00 |
| Sep 30, 2023 | 279,556.00 |
| Jun 30, 2023 | 357,664.00 |
| Jun 30, 2022 | 139,120.00 |
| Mar 31, 2022 | 115,120.00 |
| Dec 31, 2021 | 382,114.00 |
| Sep 30, 2021 | 137,552.00 |
| Jun 30, 2021 | 169,641.00 |
| Mar 31, 2021 | 65,569.00 |
| Dec 31, 2020 | 364,841.00 |
| Sep 30, 2020 | 497,999.00 |